An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives

An Evaluation of Cabozantinib for the Treatment of Renal Cell Carcinoma: Focus on Patient Selection and Perspectives

Romain Iaxx,1 Felix Lefort,1,2 Charlotte Domblides,1– 3 Alain Ravaud,1,2 Jean-Christophe Bernhard,2,4 Marine Gross-Goupil1 1Department of Medical Oncology, Hôpital Saint-André, Bordeaux University Hospital, Bordeaux, France; 2Bordeaux University, Bordeaux, France; 3ImmunoConcEpt, CNRS UMR 5164, Bord...

Full description

Bibliographic Details
Main Authors: Iaxx R, Lefort F, Domblides C, Ravaud A, Bernhard JC, Gross-Goupil M
Format: Article
Language:English
Published: Dove Medical Press 2022-06-01
Series:Therapeutics and Clinical Risk Management
Subjects:
renal cancer
cabozantinib
patient selection
prognosis
efficacy
safety
Online Access:https://www.dovepress.com/an-evaluation-of-cabozantinib-for-the-treatment-of-renal-cell-carcinom-peer-reviewed-fulltext-article-TCRM

Internet

https://www.dovepress.com/an-evaluation-of-cabozantinib-for-the-treatment-of-renal-cell-carcinom-peer-reviewed-fulltext-article-TCRM

Similar Items